DeCure's autonomous Nephrology AI scientist is researching a drug-repurposing hypothesis for lipoid nephrosis — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLipoid nephrosis maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for lipoid nephrosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
FKBP prolyl isomerase 1A (FKBP1A) — FKBP1A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 4~{s},5~{r},6~{z},9~{s},10~{s},12~{e}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6I1S · 1.52 Å · ligand (4~{S},5~{R},6~{Z},9~{S},10~{S},12~{E})-16-(ethylamino)-4,5-dimethyl-9,10,18-tris(oxidanyl)-3-oxabicyclo[12.4.0]octadeca-1(14),6,12,15,17-pentaene-2,8-dione (E26). Experimental structure, not a prediction.
What the evidence adds up to
The 1929 and 1930 papers make clear that lipoid nephrosis was a contested diagnosis from the start. Autopsy-proven cases were extremely rare; most patients did not die, and when they did, the post-mortem finding was usually glomerulonephritis with a nephrotic component, not pure lipoid nephrosis. Aschoff denied its existence altogether, and Wells stated he had looked his whole life for a pure case. Many clinically diagnosed cases were later found to be amyloidosis or specific renal tubule damage from pregnancy, infections, or intoxications.
A 1939 report on 14 patients with lipoid nephrosis claimed all were alive and considered themselves well at follow-up, with normal blood chemistry. No details are given on what treatment, if any, was used, and the paper does not provide survival times, response rates, or any quantitative outcome beyond that statement. The same author had published on the after-history of lipoid nephrosis in 1935, but that abstract is not provided.
A 1990 letter describes methylprednisolone pulse therapy in a single patient with lipoid nephrosis, reporting an effect on cellular immunity abnormalities. No clinical outcomes such as remission, proteinuria reduction, or renal function are given. The sample size is one, and there is no control.
What is still missing is any modern, controlled trial with a clear case definition, adequate sample size, and objective endpoints such as time to remission, proteinuria reduction, or preservation of renal function. The historical literature is dominated by diagnostic confusion and anecdotal reports. No funding or trial design exists that would allow a reliable test of any drug for this condition as a distinct entity.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
QJM · 1929 · 21 citations
A Study of So-Called Lipoid Nephrosis
AbstractJournal Article A Study of So-Called Lipoid Nephrosis Get access Hugh Gainsborough Hugh Gainsborough Wards and Biochemical Department of St. George's Hospital Search for other works by this author on: Oxford Academic PubMed Google Scholar QJM: An International Journal of Medicine, Volume os-23, Issue 89, October 1929, Pages 101–127, https://doi.org/10.1093/qjmed/os-23.89.101 Published: 01 October 1929 Article history Received: 17 April 1929 Published: 01 October 1929
Archives of Internal Medicine · 1930 · 16 citations
LIPOID NEPHROSIS
AbstractAs numerous as are the articles and discussions on lipoid nephrosis, so rare are the actual cases anatomically proved and reported. Few subjects in medicine have enjoyed as much speculation on as little material support or suffered as much the consequence of confusion. Of the small number of cases clinically considered, few are checked by autopsy for the excellent reason that usually the patients do not die. The great majority of those which are so checked, prove, contrary to the best supported clinical diagnoses, to be only glomerulonephritis with a nephrotic component (einschlag). Many others are so tangled up with amyloidosis that they are ordinarily ruled out of argument. The specific renal tubule damage in pregnancy and in various infections and intoxications account for still other pretenders. Aschoff finally denied altogether the existence of a genuine lipoid nephrosis. Wells 1 stated that he had looked all his life for a pure
Effect of Methylprednisolone Pulse Therapy on Cellular Immunity Abnormalities in a Patient with Lipoid Nephrosis
AbstractLetters| December 10 2008 Effect of Methylprednisolone Pulse Therapy on Cellular Immunity Abnormalities in a Patient with Lipoid Nephrosis Subject Area: Nephrology Koichi Matsumoto; Koichi Matsumoto Departments of Internal Medicine, Nihon University School of Medicine, Tokyo, and Kasukabe Municipal Hospital, Saitama, Japan Search for other works by this author on: This Site PubMed Google Scholar Miki Ito; Miki Ito Departments of Internal Medicine, Nihon University School of Medicine, Tokyo, and Kasukabe Municipal Hospital, Saitama, Japan Search for other works by this author on: This Site PubMed Google Scholar Yoshinobu Abe Yoshinobu Abe Departments of Internal Medicine, Nihon University School of Medicine, Tokyo, and Kasukabe Municipal Hospital, Saitama, Japan Search for other works by this author on: This Site PubMed Google Scholar Nephron (1990) 56 (3): 339–340. https://doi.org/10.1159/000186168 Article history Published Online: December 10 2008 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Koichi Matsumoto, Miki Ito, Yoshinobu Abe; Effect of Methylprednisolone Pulse Therapy on Cellular Immunity Abnormalities in a Patient with Lipoid Nephrosis. Nephron 1 March 1990; 56 (3): 339–340. https://doi.org/10.1159/000186168 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsNephron Search Advanced Search Article PDF first page preview Close Modal 1990Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. You do not currently have access to this content.
AbstractArticle1 April 1939OBSERVATIONS ON THE TREATMENT OF LIPOID NEPHROSISRALPH H. MAJOR, M.D.RALPH H. MAJOR, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-12-10-1555 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe disease known as chronic nephrosis or lipoid nephrosis has been the subject of continued dispute since the initial publications of Munk and of Epstein. Opinion still seems to be divided as to whether it is a type of glomerulonephritis or a distinct clinical and pathological entity. There is apparently an increasing amount of opinion favoring the latter view.In a series of 14 patients, who have been carefully followed since their dismissal from the hospital, all are alive and consider themselves well. All of the 14 show at the present time a normal blood chemistry and are entirely free...Bibliography1. BESTHUNTSMAN CHME: The effects of the components of lecithine upon deposition of fat in the liver, Jr. Physiol., 1932, lxxv, 405. CrossrefGoogle Scholar2. COLLIP JB: Chemistry and physiology of anterior pituitary hormones, Trans. Congr. Am. Phys. and Surg., Fifteenth Session, 47. Google Scholar3. MAJOR RH: The after-history of lipoid nephrosis, Trans. Assoc. Am. Phys., 1935, l, 128. Google Scholar4. THADDEAFASSHAUER SW: Nebennierenrinde und Cholesterinstoffwechsel, Arch. f. exper. Path. u. Pharmakol., 1936, clxxxii, 477. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Kansas City, Kansas*Received for publication March 4, 1938.From the Department of Internal Medicine, University of Kansas School of Medicine. Kansas City, Kansas. Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDegenerative Nierenerkrankungen 1 April 1939Volume 12, Issue 10Page: 1555-1559KeywordsBlood chemistryGlomerulonephritis ePublished: 1 December 2008 Issue Published: 1 April 1939 Copyright & PermissionsCopyright, 1939, by The American College of PhysiciansPDF downloadLoading ...
THE NEPHROSIS SYNDROME ASSOCIATED WITH TERMINAL UREMIA
AbstractCase Reports1 September 1936THE NEPHROSIS SYNDROME ASSOCIATED WITH TERMINAL UREMIAPAUL H. WOSIKA, M.D.PAUL H. WOSIKA, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-10-3-403 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptNumerous cases of so-called "pure," "genuine" or "lipoid" nephrosis have been described in the literature. A close inspection of these reveals that very few cases in adults conform to the rigid rules clearly stated by Leiter1in his review of the subject in 1931. Using the clinical criteria mentioned as necessary to establish the diagnosis, several authors have published reports of groups of cases of nephrosis, whereas other authors equally interested in the problem of renal disease state that true "lipoid nephrosis" has never been observed by them. Christian2in summarizing the reported cases, was impressed by the short duration...References1. LEITER L: Nephrosis, Medicine, 1931, x, 135. CrossrefGoogle Scholar2. CHRISTIAN HA: Nephrosis: a critique, Jr. Am. Med. Assoc., 1929, xciii, 23. CrossrefGoogle Scholar3. BELL ET: Lipoid nephrosis, Am. Jr. Path., 1929, v, 587. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Chicago, Illinois*Received for publication August 16, 1935.From the Medical Clinic of the Peter Bent Brigham Hospital, Boston, Mass.Department of Medicine, Northwestern University Medical School, Chicago, Ill. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDegenerative Nierenerkrankungen 1 September 1936Volume 10, Issue 3Page: 403-410KeywordsPathologistsRenal diseases Issue Published: 1 September 1936 PDF downloadLoading ...
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
